To The Moon

On Friday, shares of Novo Nordisk (NVO.US) advanced in pre-market trading. At the time of writing, the stock was up more than 3.6%, trading at $59.41. Amazon's digital pharmacy announced it has begun offering Novo Nordisk's weight-loss drug, Wegovy oral tablets, through its platform. This is currently the first and only oral GLP-1 medication approved by the U.S. FDA for weight management. According to the announcement, eligible commercial health insurance users purchasing Wegovy oral tablets through Amazon Pharmacy could have a monthly out-of-pocket cost as low as $25; consumers without insurance can opt for a transparent cash-pay plan starting at $149 per month. Amazon Pharmacy stated that its platform allows users to compare insurance-covered prices and cash-pay prices side-by-side, with the system automatically applying eligible coupons at checkout to help consumers choose the most suitable payment method. Furthermore, the platform offers fast home delivery of Wegovy oral tablets to all 50 U.S. states, with approximately half of American users also eligible for same-day delivery service. Market observers pointed out that this move not only further expands the accessibility of Wegovy but also highlights Amazon's continued strategic focus on strengthening its presence in the healthcare and prescription drug distribution sector. Against the backdrop of persistently high demand for GLP-1 weight-loss drugs, the involvement of e-commerce and digital health platforms could have a more profound impact on traditional pharmacies and drug distribution channels.